The iTrack Advance device. Source: Nova Eye Medical
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • US sales revenue for Nova Eye Medical (ASX:EYE) surged 65 per cent to US$7.5 million in the six months ending December 31, 2023
  • The growth was fuelled by the positive reception of the iTrack™ Advance, despite a temporary setback due to Medicare reimbursement uncertainties
  • Proposal withdrawal by Medicare Administrative Contractors paves the way for higher sales growth in the second half of the fiscal year
  • Nova Eye Medical anticipates unveiling global sales results for the period ending December 2023 in early February 2024
  • EYE last traded at 29.5 cents

Nova Eye Medical (ASX:EYE) has reported a 65 per cent surge in USA sales revenue, reaching US$5.1 million for the six months ending December 31, 2023.

The performance is attributed to the strong adoption of the innovative iTrack™ Advance, which was launched in the US in May 2023.

Despite achieving market penetration since the introduction of iTrack™ Advance, Nova Eye Medical encountered a challenge during November and December 2023.

The proposal by five Medicare Administrative Contractors (MACs) to limit reimbursement coverage for various minimally invasive glaucoma surgery (MIGS) procedures, including canaloplasty, temporarily impacted sales growth.

However, the landscape changed positively with the withdrawal of these proposed reimbursement changes by the MACs on December 29, 2023.

Nova Eye Medical now anticipates a clear runway for higher sales growth in the second half of the 2024 fiscal year, as confirmed by the company.

“The withdrawal of the LCDs on 29 December 2023 and the confirmation of continued reimbursement coverage for the Company’s iTrack™ portfolio provides a clear runway for higher sales growth,” Company Secretary Simon Gray said.

The company remains optimistic about the global sales scenario, with unaudited results for the period ending December 31, 2023, expected to be released during the week commencing February 5, 2024.

Nova Eye Medical last traded at 29.5 cents.

EYE by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…